Sanofi (NASDAQ:SNY) Receives $49.50 Consensus Target Price from Analysts

Sanofi (NASDAQ:SNY) has been given an average rating of “Hold” by the fifteen ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating, three have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $49.50.

Several brokerages have commented on SNY. Morgan Stanley set a $49.00 target price on Sanofi in a report on Wednesday, July 8th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Citigroup reiterated a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Monday, April 20th. Finally, Argus upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNY. Fiduciary Financial Group LLC boosted its holdings in Sanofi by 33.8% in the second quarter. Fiduciary Financial Group LLC now owns 8,403 shares of the company’s stock worth $358,000 after purchasing an additional 2,124 shares during the last quarter. Fulton Bank N.A. raised its stake in Sanofi by 5.6% during the 2nd quarter. Fulton Bank N.A. now owns 68,196 shares of the company’s stock valued at $2,909,000 after buying an additional 3,623 shares during the last quarter. First Bank & Trust raised its stake in Sanofi by 23.4% during the 2nd quarter. First Bank & Trust now owns 83,933 shares of the company’s stock valued at $3,581,000 after buying an additional 15,937 shares during the last quarter. Focus Financial Network Inc. lifted its holdings in shares of Sanofi by 9.2% during the 2nd quarter. Focus Financial Network Inc. now owns 5,302 shares of the company’s stock valued at $226,000 after buying an additional 446 shares during the period. Finally, Valeo Financial Advisors LLC lifted its holdings in shares of Sanofi by 11.0% during the 2nd quarter. Valeo Financial Advisors LLC now owns 5,730 shares of the company’s stock valued at $244,000 after buying an additional 568 shares during the period. Institutional investors own 14.03% of the company’s stock.

Sanofi Trading Up 0.2%

Shares of NASDAQ SNY opened at $42.78 on Monday. The firm’s 50 day moving average price is $43.34 and its 200-day moving average price is $45.09. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The company has a market cap of $103.72 billion, a PE ratio of 22.40, a P/E/G ratio of 1.07 and a beta of 0.35.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.